Regulatory Framework for Drugs Approval

Version 6.2

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of issue</td>
<td>15 July 2008</td>
</tr>
<tr>
<td>Date of implementation</td>
<td>1 October 2020</td>
</tr>
</tbody>
</table>
Regulatory Framework for Drugs Approval

Version 6.2

Saudi Food & Drug Authority
Drug Sector

For Inquiries  SDR.Drug@sfda.gov.sa
For Comments  Drug.Comments@sfda.gov.sa

Please visit SFDA’s website at for the latest update
Saudi Food and Drug Authority

Vision and Mission

**Vision**
To be a leading international science-based regulator to protect and promote public health

**Mission**
Protecting the community through regulations and effective controls to ensure the safety of food, drugs, medical devices, cosmetics, pesticides and feed
## Document Control

<table>
<thead>
<tr>
<th>Version</th>
<th>Author</th>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Licensing department</td>
<td>15 March 2008</td>
<td>Initial draft for internal consultation</td>
</tr>
<tr>
<td>2.0</td>
<td>Licensing department</td>
<td>15 July 2008</td>
<td>Published for comments</td>
</tr>
<tr>
<td>3.0</td>
<td>Licensing department</td>
<td>19 January 2009</td>
<td>Revised draft</td>
</tr>
<tr>
<td>4.0</td>
<td>Licensing department</td>
<td>5 July 2009</td>
<td>Final version posted</td>
</tr>
<tr>
<td>5.0</td>
<td>Regulatory Affairs</td>
<td>16 March 2014</td>
<td>Update</td>
</tr>
<tr>
<td>6.0</td>
<td>Executive Directorate of Regulatory Affairs</td>
<td>17 March 2019</td>
<td>Update and published for comments purposes</td>
</tr>
<tr>
<td>6.1</td>
<td>Executive Directorate of Regulatory Affairs</td>
<td>1 September 2020</td>
<td>Update</td>
</tr>
<tr>
<td>6.2</td>
<td>Executive Directorate of Regulatory Affairs</td>
<td>12 October 2021</td>
<td>Update (Next page shows the updated details)</td>
</tr>
</tbody>
</table>
What is New in version no. 6.2?

The following table shows the update to the previous version:

<table>
<thead>
<tr>
<th>Section</th>
<th>Description of change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glossary</strong></td>
<td><strong>Update:</strong></td>
</tr>
<tr>
<td></td>
<td>Glossary</td>
</tr>
<tr>
<td></td>
<td>- Generic (multisource) product</td>
</tr>
<tr>
<td></td>
<td>➢ <strong>Note:</strong></td>
</tr>
<tr>
<td></td>
<td>A drug application will be considered as generic if the innovative product is registered in one of the SRA irrespective of whether the innovative product is registered or not at SFDA.</td>
</tr>
<tr>
<td><strong>4. variation of marketing</strong></td>
<td><strong>Update:</strong></td>
</tr>
<tr>
<td><strong>authorization</strong></td>
<td>A. Minor changes</td>
</tr>
<tr>
<td></td>
<td>- Type IA</td>
</tr>
</tbody>
</table>
Table of Contents:

ACRONYMS AND ABBREVIATIONS ........................................................................................................ 8
GLOSSARY ............................................................................................................................................. 9
1. INTRODUCTION .............................................................................................................................. 12
2. SCOPE ............................................................................................................................................. 12
3. NEW MARKETING AUTHORIZATION APPLICATION (MAA) ..................................................... 13
   3.1. SUBMISSION ............................................................................................................................ 13
   3.1.1. ONLINE SUBMISSION ........................................................................................................ 13
   3.1.2. VALIDATION ....................................................................................................................... 13
   3.1.2.1. TECHNICAL VALIDATION ............................................................................................ 13
   3.1.2.2. BUSINESS VALIDATION .............................................................................................. 13
   3.2. ASSESSMENT ........................................................................................................................... 14
   3.2.1. EVALUATION / INSPECTION ........................................................................................... 14
   3.2.2. TESTING ............................................................................................................................ 15
3.3. PRICING ....................................................................................................................................... 15
3.4. PRODUCT LICENSING ................................................................................................................. 16
3.5. REGISTRATION PERFORMANCE TARGETS ............................................................................. 17
   3.5.1. REGULAR REVIEW PATHWAY ......................................................................................... 17
   3.5.2. PRIORITY REVIEW PATHWAY (40% REDUCTION): ............................................................ 18
   3.5.3. VERIFICATION & ABRIDGED PATHWAY: ......................................................................... 18
4. VARIATION OF MARKETING AUTHORIZATION ............................................................................. 19
   4.1. SUBMISSION ............................................................................................................................ 19
   4.1.1. ONLINE SUBMISSION ........................................................................................................ 19
   4.1.2. BUSINESS VALIDATION ................................................................................................... 20
   4.2. ASSESSMENT ........................................................................................................................... 20
   4.2.1. EVALUATION / INSPECTION: .......................................................................................... 20
   4.3. PRICING ................................................................................................................................... 21
   4.4 PRODUCT LICENSING ................................................................................................................. 21
4.5. VARIATION PERFORMANCE TARGETS: .................................................................................... 23
5. RENEWAL OF MARKETING AUTHORIZATION .............................................................................. 24
   5.1. SUBMISSION ............................................................................................................................ 24
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.1.1. ONLINE SUBMISSION:</td>
<td>24</td>
</tr>
<tr>
<td>5.1.2. BUSINESS VALIDATION:</td>
<td>24</td>
</tr>
<tr>
<td>5.2. PRICING</td>
<td>25</td>
</tr>
<tr>
<td>5.3. PRODUCT LICENSING</td>
<td>25</td>
</tr>
<tr>
<td>5.4. RENEWAL PERFORMANCE TARGETS:</td>
<td>26</td>
</tr>
<tr>
<td>6. APPENDIX</td>
<td>27</td>
</tr>
<tr>
<td>6.1. APPLICATION FORMS</td>
<td>27</td>
</tr>
</tbody>
</table>
Acronyms and Abbreviations

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>API</td>
<td>Active Pharmaceutical Ingredients</td>
</tr>
<tr>
<td>ATC</td>
<td>Anatomical Therapeutic Chemical Classification System</td>
</tr>
<tr>
<td>ATC vet</td>
<td>Anatomical Therapeutic Chemical Classification System for veterinary products</td>
</tr>
<tr>
<td>BSE</td>
<td>Bovine spongiform encephalopathy</td>
</tr>
<tr>
<td>CEO</td>
<td>Chief Executive Officer</td>
</tr>
<tr>
<td>COO</td>
<td>Country of Origin</td>
</tr>
<tr>
<td>CPP</td>
<td>Certificate of Pharmaceutical Product</td>
</tr>
<tr>
<td>CTD</td>
<td>Common Technical Document</td>
</tr>
<tr>
<td>EMA</td>
<td>European Medicines Agency</td>
</tr>
<tr>
<td>KSA</td>
<td>Kingdom of Saudi Arabia</td>
</tr>
<tr>
<td>MA</td>
<td>Marketing Authorization</td>
</tr>
<tr>
<td>MAA</td>
<td>Marketing Authorization Application</td>
</tr>
<tr>
<td>MAH</td>
<td>Marketing Authorization Holder</td>
</tr>
<tr>
<td>MHRA</td>
<td>Medicines and Healthcare products Regulatory Agency</td>
</tr>
<tr>
<td>NCE</td>
<td>New Chemical Entity</td>
</tr>
<tr>
<td>NPC</td>
<td>National Pharmacovigilance Center</td>
</tr>
<tr>
<td>RA</td>
<td>Regulatory Affairs</td>
</tr>
<tr>
<td>SDR</td>
<td>Saudi Drug Registration system</td>
</tr>
<tr>
<td>SFDA</td>
<td>Saudi Food and Drug Authority</td>
</tr>
<tr>
<td>Swissmedic</td>
<td>Swiss Agency for Therapeutic Products</td>
</tr>
<tr>
<td>TGA</td>
<td>Therapeutic Goods Administration</td>
</tr>
<tr>
<td>TSE</td>
<td>Transmissible Spongiform Encephalopathy</td>
</tr>
<tr>
<td>US FDA</td>
<td>United States Food and Drug Administration</td>
</tr>
</tbody>
</table>
# Glossary

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant</td>
<td>The company or its representative</td>
</tr>
<tr>
<td>Biologics</td>
<td>Medicinal products derived from a variety of natural sources or produced by biotechnology methods and other cutting-edge technologies. They include a wide range of products such as vaccines, blood and blood components, allergenics, advanced therapy medicinal products (ATMPs), recombinant proteins and biosimilars</td>
</tr>
<tr>
<td>Biosimilars</td>
<td>Therapeutic proteins produced by recombinant DNA technology or gene expression method following the footsteps of one licensed reference biotechnological product. They are complex and heterogeneous in their nature; hence they are not considered generics, but as closely similar to the innovator’s drug as possible</td>
</tr>
<tr>
<td>Blood products</td>
<td>They are a wide range of medicinal product sourced from human blood or plasma (source material) that can be collected and tested at “Blood Establishments” and obtained by industrial process “Fractionation” of human plasma of a large number of donations (up to tens of thousands) that are pooled together</td>
</tr>
<tr>
<td>Common Technical Document (CTD)</td>
<td>An international harmonized format for submissions for approval of pharmaceuticals. The CTD provides a standardization of the presentation of the content</td>
</tr>
<tr>
<td>Dosage form</td>
<td>The finished formulation of a pharmaceutical product, e.g. tablet, capsule, suspension, solution for injection, suppository</td>
</tr>
<tr>
<td>Drug</td>
<td>An article intended for use in the diagnosis, cure mitigation, treatment, or prevention of disease and which is intended to affect the structure or function of the body</td>
</tr>
<tr>
<td>Drug Application</td>
<td>A drug application includes the application form and the product file</td>
</tr>
<tr>
<td>Generic (multisource) product</td>
<td>A product created to be equivalent to the innovative / brand name product in dosage form, strength, route of administration, quality, performance characteristics and therapeutic indication(s)</td>
</tr>
</tbody>
</table>

➤ **Note:**
A drug application will be considered as generic if the innovative product is registered in one of the SRA irrespective of whether the innovative product is registered or not at SFDA.

<table>
<thead>
<tr>
<th>Health product</th>
<th>Refer to the SFDA classification guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herbal product</td>
<td>Any finished labeled medicinal products that contain as active ingredients aerial or underground parts of plants or other plant materials or the combination of them, whether in crude state or plant preparation that is used to treat or prevent diseases or ailments or to promote health and healing. Plant materials include juices, gums, fatty oils and any other substance of this nature</td>
</tr>
<tr>
<td>Inquiry</td>
<td>A questions or clarifications posted in SDR system to be responded by the applicant</td>
</tr>
<tr>
<td>New (innovative) product</td>
<td>A product that includes new chemical entity and introduced by the innovator company (or the partner)</td>
</tr>
<tr>
<td>Novel recombinant protein</td>
<td>Novel medicinal products produced by biotechnology methods and other cutting-edge technologies. They include a wide range of recombinant products such as enzymes, hormones, monoclonal antibodies; except blood products and vaccines.</td>
</tr>
<tr>
<td>Medicinal gas</td>
<td>Any gas or mixture of gases classified as a medicinal product</td>
</tr>
<tr>
<td>Radiopharmaceutical product</td>
<td>A radioactive drug that can be administered safely to humans for diagnostic and therapeutic purposes.</td>
</tr>
<tr>
<td>Reference number / sub-product number</td>
<td>Any combination of letters and numbers that is assigned to the transaction in order to follow it.</td>
</tr>
<tr>
<td>Renewal of marketing authorization</td>
<td>A process of renewing the marketing authorization license every five years.</td>
</tr>
<tr>
<td>SADAD</td>
<td>A system that links between the commercial sector and the local banks; it offers the ability to collect its customer payment electronically through all banking channels in KSA around the clock.</td>
</tr>
<tr>
<td>SFDA’s pricing rules</td>
<td>The Rules for Pharmaceutical Products Pricing which include the general requirements and criteria for pricing a pharmaceutical product and constitute the general framework of the “Pharmaceutical Products Pricing Committee” to suggest the price.</td>
</tr>
<tr>
<td><strong>Product file</strong></td>
<td>The electronic version of the product file.</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------------------------------------</td>
</tr>
</tbody>
</table>
| **Stringent Regulatory Authority (SRA)** | **For human products:** USFDA, EMA, MHRA (UK), Swissmedic, Health Canada and TGA (Australia).  
**For veterinary products:** European Medicine Agency, Veterinary Medicines Directorate (UK), Health Canada Drug Product Database, Australian Pesticides and Veterinary Medicines Authority, Food and Drug Administration (USA), The French Agency for Veterinary Medicinal Products, Health Product Regulatory Authority (Ireland), Federal Office of Consumer protection and Food Safety & Paul Ehrlich Institute (Germany), New Zealand Food Safety, Federal Agency for Medicines and Health Products (Belgium), The Netherlands Veterinary Medicines Institute and Spanish Agency of Medicines and Medical Devices (Spain). |
| **Validation (Business & technical)** | The process of checking if documents satisfy a certain criterion |
| **Vaccines** | Preparations that contain antigenic substances capable of inducing a specific and active immunity against the infecting agent or the toxin or the antigen produced by it. |
| **Variation** | A process of informing SFDA of any minor or major changes in the drug product. |
| **Veterinary product** | Any substance or combination of substances presented as having properties for treating or preventing disease in animals; or any substance or combination of substances that may be used in, or administered to, animals with a view either to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis. |
| **Wave** | Set of inquiries from one or multiple departments sent to applicants during assessment process. |
1. INTRODUCTION

The Drug Sector in Saudi Food & Drug Authority (SFDA) has developed this administrative document to provide assistance for stakeholders on how to submit applications for various types of drug products and the procedure to authorize the applications.

Besides the Market Authorization Application (MAA) of various types of drug products, it also describes variations applications and renewal of MAA. Various application forms and time-frame for processing applications to marketing the product in Saudi Arabia are also included in this document.

2. Scope:

This framework applicable to all types of drug product submitted for registration, variation or renewal.
3. NEW MARKETING AUTHORIZATION APPLICATION (MAA) 1

The MAA of pharmaceutical product will be subjected to the followings processes:

3.1. Submission

The process of submitting a new MAA consists of two steps:

3.1.1. Online submission

1. The applicant shall apply through SDR system to fill the application form and pay the fees.
2. Upload the product file; The components of the file shall follow the requirements and guidelines published on SFDA website.

3.1.2. Validation

The product file will be validated in technical and business bases to ensure the applicant fulfills the requirement. The validation involves two steps:

3.1.2.1. Technical validation

SDR system will validate the submission automatically after the company upload the file on the SDR portal. The validation’s result will be sent by email through SDR system to the applicant.

3.1.2.2. Business validation

1. The product file will be validated to ensure that all information provided is according to the requirements and guidelines.
2. If any information is missing or incorrect, an electronic inquiry will be forwarded to the applicant through the SDR system. The applicant will be given an opportunity to complete the file within 30 working days.
3. The completed file will proceed to the next steps for Assessment (section 3.2).

---

1 Performance targets for every step are provided at the end of this part (section 3.5) for all pathways (Regular, Priority, Verification and Abridged)
The registration request will be rejected in the following cases:

- No response from the applicant within 30 working days.
- Failure to provide acceptable clarifications after the third wave.

3.2. Assessment

The MAA for different drug submission types subject to the following processes:

3.2.1. Evaluation / Inspection

1. The RA will distribute the registration request to the relevant related departments to assess quality, safety and efficacy;
   - For Inspection: the department will check the approval of manufacturing line; if not approved:
Visit will be scheduled for inspection depending on the time available for both inspectors and the company.

After the visit, the inspection report will be sent to the company (please, refer to *the Good Manufacturing Practice for Medicinal product*).

2. If more information or clarification is required, an electronic inquiry will be posted through SDR system as one wave for evaluation and inspection. A response should be received within 60 working days.

3. Once the evaluation and inspection are completed, the registration request will be forwarded to Pricing (section 3.3)

3.2.2. Testing

1. The registration request will be forwarded to the SFDA Central Laboratories.

2. If more information or clarification is required, an electronic inquiry will be posted through SDR system.

Note: Testing will not delay the registration of a product.

3.3. Pricing

1. The Pricing Department will review product’s price according to the “*SFDA’s pricing rules*”.

2. If more information or clarification is required, an electronic inquiry will be posted through SDR system. A response should be received within 60 working days.

3. The product’s price will be forwarded to Registration Committee (section 3.4).

The registration request will be rejected in the following cases:

- No response from the applicant within 60 working days.
- Failure to provide acceptable clarifications after the 4th wave.

Important Note:

The applicant will have a total of four (4) waves for Evaluation / inspection and Pricing.
3.4. Product licensing

1. The Registration Committee will review the registration request for approval, rejection or ask for further information (if needed).

2. The SFDA CEO will approve the meeting minutes.

3. For approved registration request, the applicant will be notified through SDR system to issue the MA.

Appeal Process:

The applicant has the right to appeal against any decision within 60 calendar days, for more information refer to Guidance for Submission.

Figure 2 schematic figure showing the different levels for getting a marketing authorization (section 3.2, 3.3 and 3.4)
3.5. Registration performance targets

- The performance target in any step will STOP if a clarification or information is needed from the applicant, and resume after receiving the response.
- All days are considered as working days.
- Total Performance Target calculated without the Business Validation for all pathways

### 3.5.1. Regular review pathway

<table>
<thead>
<tr>
<th>Registration phases</th>
<th>Technical Validation</th>
<th>Business Validation</th>
<th>Evaluation / Inspection</th>
<th>Pricing</th>
<th>Product licensing</th>
<th>Total Performance Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of Waves</td>
<td>section 3.1.2.1</td>
<td>section 3.1.2.2</td>
<td>section 3.2.1</td>
<td>section 3.3</td>
<td>section 3.4</td>
<td></td>
</tr>
<tr>
<td>Human Generic</td>
<td>-</td>
<td>3</td>
<td>120</td>
<td>20</td>
<td>15</td>
<td>155</td>
</tr>
<tr>
<td>Human New Drugs</td>
<td>-</td>
<td>10</td>
<td>245</td>
<td>20</td>
<td>15</td>
<td>280</td>
</tr>
<tr>
<td>registered in SRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human New Drugs</td>
<td>-</td>
<td>10</td>
<td>370</td>
<td>20</td>
<td>15</td>
<td>405</td>
</tr>
<tr>
<td>not registered in SRA</td>
<td>-</td>
<td>10</td>
<td>245</td>
<td>20</td>
<td>15</td>
<td>280</td>
</tr>
<tr>
<td>Human Biologics</td>
<td>-</td>
<td>10</td>
<td>370</td>
<td>20</td>
<td>15</td>
<td>405</td>
</tr>
<tr>
<td>registered in SRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Biologics</td>
<td>-</td>
<td>10</td>
<td>370</td>
<td>20</td>
<td>15</td>
<td>405</td>
</tr>
<tr>
<td>not registered in SRA</td>
<td>-</td>
<td>10</td>
<td>245</td>
<td>20</td>
<td>15</td>
<td>280</td>
</tr>
<tr>
<td>Radiopharmaceuticals</td>
<td>-</td>
<td>10</td>
<td>120</td>
<td>20</td>
<td>15</td>
<td>155</td>
</tr>
<tr>
<td>Veterinary Generics</td>
<td>-</td>
<td>10</td>
<td>150</td>
<td></td>
<td>15</td>
<td>165</td>
</tr>
<tr>
<td>Veterinary New Drugs</td>
<td>-</td>
<td>10</td>
<td>245</td>
<td></td>
<td>15</td>
<td>260</td>
</tr>
<tr>
<td>registered in SRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Veterinary New Drugs</td>
<td>-</td>
<td>10</td>
<td>370</td>
<td></td>
<td>15</td>
<td>385</td>
</tr>
<tr>
<td>not registered in SRA</td>
<td>-</td>
<td>10</td>
<td>245</td>
<td></td>
<td>15</td>
<td>260</td>
</tr>
<tr>
<td>Veterinary Biologics</td>
<td>-</td>
<td>10</td>
<td>370</td>
<td></td>
<td>15</td>
<td>385</td>
</tr>
<tr>
<td>registered in SRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herbal &amp; health</td>
<td>-</td>
<td>10</td>
<td>120</td>
<td>20</td>
<td>15</td>
<td>155</td>
</tr>
<tr>
<td>products</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### 3.5.2. Priority review pathway (40% reduction)²:

<table>
<thead>
<tr>
<th>Registration phases</th>
<th>Technical Validation</th>
<th>Business Validation</th>
<th>Evaluation / Inspection</th>
<th>Pricing</th>
<th>Product licensing</th>
<th>Total Performance target</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>section 3.1.2.1</td>
<td>section 3.1.2.2</td>
<td>section 3.2.1</td>
<td>section 3.3</td>
<td>section 3.4</td>
<td></td>
</tr>
<tr>
<td>No. of Waves</td>
<td>-</td>
<td>3</td>
<td>4</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Generic</td>
<td>-</td>
<td>10</td>
<td>72</td>
<td>12</td>
<td>9</td>
<td>93</td>
</tr>
<tr>
<td>Human New Drugs</td>
<td>-</td>
<td>10</td>
<td>147</td>
<td>12</td>
<td>9</td>
<td>168</td>
</tr>
<tr>
<td>registered in SRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human New Drugs</td>
<td>-</td>
<td>10</td>
<td>222</td>
<td>12</td>
<td>9</td>
<td>243</td>
</tr>
<tr>
<td>not registered in SRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Biologics</td>
<td>-</td>
<td>10</td>
<td>147</td>
<td>12</td>
<td>9</td>
<td>168</td>
</tr>
<tr>
<td>registered in SRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Biologics</td>
<td>-</td>
<td>10</td>
<td>222</td>
<td>12</td>
<td>9</td>
<td>243</td>
</tr>
<tr>
<td>not registered in SRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiopharmaceuticals</td>
<td>-</td>
<td>10</td>
<td>147</td>
<td>12</td>
<td>9</td>
<td>168</td>
</tr>
</tbody>
</table>

### 3.5.3. Verification & abridged pathway³:

<table>
<thead>
<tr>
<th>Registration phases</th>
<th>Technical validation</th>
<th>Business validation</th>
<th>Evaluation / Inspection</th>
<th>Pricing</th>
<th>Product licensing</th>
<th>Total Performance target</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>section 3.1.2.1</td>
<td>section 3.1.2.2</td>
<td>section 3.2.1</td>
<td>section 3.3</td>
<td>section 3.4</td>
<td></td>
</tr>
<tr>
<td>No. of Waves</td>
<td>-</td>
<td>3</td>
<td>4</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verification</td>
<td>-</td>
<td>5</td>
<td>15</td>
<td>5</td>
<td>10</td>
<td>30</td>
</tr>
<tr>
<td>Abridged</td>
<td>-</td>
<td>5</td>
<td>40</td>
<td>10</td>
<td>10</td>
<td>60</td>
</tr>
</tbody>
</table>

² Refer to the Guidance for Priority Review of Product Registration
³ Refer to the Registration According to Verification and Abridged
4. VARIATION OF MARKETING AUTHORIZATION

Any changes on a registered product has to be submitted to the SFDA as a Variation of MAA. The variations are classified into two main categories:

A. Minor variations

- **Type IA**: Such minor variations do not require prior approval before implementation (“Do and Tell” procedure). Type IA variations should be submitted immediately, within 14 days following implementation. Other type IA variations, however, can be compiled in a single variation application, to be submitted to the SFDA no later than January 31st of each year.

- **Type IB**: minor variations that must be submitted to the SFDA by MAH before implementation, but do not require a formal approval. However, the MAH must wait a period of 60 working days to ensure that the application is deemed acceptable by the SFDA before implementing the change (“Tell, Wait and Do” procedure).

B. Major variations

- **Type II**: major variations in which there might be a significant impact on the Quality, Safety or Efficacy of a pharmaceutical product and require prior approval before implementation.

The variation request subjects to the following process:

4.1. Submission

The process of submitting a variation of MAA consists of two steps:

4.1.1. Online submission

1. The applicant shall apply through SDR system to fill the application form and pay the fees.

2. Upload the product file; The components of the file shall follow the requirements and guidelines published on SFDA website.

---

4 Performance targets for each step are provided at the end of this part (section 4.5)

5 Refer to the GCC Guidelines for Variation Requirements
For applications made via the new SDR system, three parallel variation applications can be submitted at a time, each includes administrative, quality or safety variations. Each category of variations will be assigned to the related departments.

4.1.2. Business Validation

1. The product file will be validated to ensure that all information provided is according to the requirements and/or guidelines.
2. If any information is missing or incorrect, an electronic inquiry will be forwarded to the applicant through the SDR system. The applicant will be given an opportunity to complete the file within 30 working days.
3. The completed file will proceed to the next step for Assessment (section 4.2).

The variation request will be rejected in the following cases:

- No response from the applicant within 30 working days.
- Failure to provide acceptable clarifications after the second wave.

4.2. Assessment

Depending on the type of variation, one or more department may review the variation application.

4.2.1. Evaluation / Inspection:

1. The variation request will be distributed to the relevant related department – as needed;
   - For the inspection related requests: the department will check the approval of manufacturing line, if not approved:
     - Visit will be scheduled for inspection depending on the time available for both inspectors and the company.
     - After the visit, the inspection report will be sent to the company (please, refer to the guidance of Good Manufacturing Practice for Medicinal product).

2. If more information or clarification is required, an electronic inquiry will be posted through SDR system. The response should be received within 60 working days.
3. Reports (recommendation for approval or rejection) will be collected by the RA.

4. The reports will be forwarded (if needed) to pricing (section 4.3) and registration committee (section 4.4) depending on the type of variation.

4.3. Pricing

1. The Pricing Department handles all variation requests that require pricing review according to “SFDA’s pricing rules”.

2. If more information or clarification is required, an electronic Inquiry will be posted through SDR system. A response should be received within 60 working days.

3. The approved price will be forwarded to the Registration Committee (section 4.4).

The variation request will be rejected in the following cases:

- No response from the applicant within 60 working days.
- Failure to provide acceptable clarifications after the third wave.

Important Note:

The applicant will have a total of three (3) waves for Assessment and Pricing

4.4. Product Licensing

- For all variation types except variation affecting product price:
  1. The RA will approve the final report.
  2. Notify the applicant through SDR system.

- For variation affecting product price:
  1. The Registration Committee will review the variation request for approval, rejection or ask for further information (if needed).
  2. The SFDA CEO will approve the meeting minutes.
  3. For approved variation request, the applicant will be notified through SDR system.
General variation notes:

- For applications made via the new SDR system; after the completion of an application of a particular category (by approval or rejection), another application of the same category can be submitted.
- For application includes more than one type of variation, the longest duration in total performance target will be considered. For example: application includes type 1B and type II, the total performance target for the application is 100 working days.

Appeal Process:
The applicant has the right to appeal within 60 calendar days of the SFDA’s final decision, for more information refer to Guidance for submission.

**Figure 3** Schematic figure showing the workflow of Variation
4.5. Variation performance targets:

- The performance target in any step will STOP if a clarification or information is needed from the applicant, and resume after receiving the response.
- All days below are considered as working days.
- Total Performance Target calculated without the Business Validation for all types of variations.

<table>
<thead>
<tr>
<th>Phases</th>
<th>Business Validation</th>
<th>Assessment</th>
<th>Pricing</th>
<th>Product licensing</th>
<th>Total Performance target</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>section 4.1.2</td>
<td>section 4.2</td>
<td>section 4.3</td>
<td>section 4.4</td>
<td></td>
</tr>
<tr>
<td>No. of Waves</td>
<td>2</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Type I A</td>
<td>5</td>
<td>20</td>
<td>-</td>
<td>10</td>
<td>30</td>
</tr>
<tr>
<td>Type I B</td>
<td>5</td>
<td>40</td>
<td>10</td>
<td>10</td>
<td>60</td>
</tr>
<tr>
<td>Type II</td>
<td>5</td>
<td>80</td>
<td>10</td>
<td>10</td>
<td>100</td>
</tr>
</tbody>
</table>
5. RENEWAL OF MARKETING AUTHORIZATION\textsuperscript{6}

An applicant shall submit a renewal request every five years\textsuperscript{7}. It is possible to request for renewal within six months of the certificate expiry.

As most of the registered drugs have went through at least one renewal process or have been registered through SDR system; therefore, the renewal process is shorter as follows:

5.1. Submission

The process of submitting a renewal of MA consists of two steps:

5.1.1. Online submission:

1. The applicant shall apply through SDR system to fill the application form and pay the fees.
2. Upload the renewal file; The components of the file shall follow the requirements and guidelines published on SFDA website.

5.1.2. Business Validation:

1. The product file will be validated to ensure that all information provided are according to the requirements and/or guidelines.
2. If any information is missing or incorrect, an electronic Inquiry will be forwarded to the applicant through SDR system. The applicant will be given an opportunity to complete the file within 30 working days.
3. The completed file will proceed to the Pricing Department (section 5.2).

The renewal request will be rejected in the following cases:

- No response from the applicant within 30 working days.
- Failure to provide acceptable clarifications after the first wave

\textsuperscript{6} Performance targets for each step are provided at the end of this part (section 5.4)
\textsuperscript{7} For Human Medicinal products refer to the GCC Data Requirements for the Renewal of MA, For Veterinary Medicinal products refer to the Data Requirements for Renewal the MA of Veterinary Medicinal Products
5.2. Pricing

1. The Pricing Department will review the price according to the “SFDA’s pricing rules”.

2. If more information or clarification is required, an electronic inquiry will be posted through SDR system. A response should be received within 60 working days.

3. The approved price will be forwarded to the product licensing (section 5.3).

The renewal request will be rejected in the following cases:

- No response from the applicant within 60 working days.
- Failure to provide acceptable clarifications after the first wave.

5.3. Product Licensing

1. The RA will issue the renewal of MA.

2. The applicant will be notified through SDR system.

Important Note:

The rejected renewal applications obligate the applicant to submit a new one.
**Appeal Process:**
The applicant has the right to appeal within 60 calendar days of the SFDA’s final decision, for more information refer to Guidance for submission.

**Figure 4** Schematic figure showing the renewal process of a marketing authorization

**5.4. Renewal performance targets:**
- The performance target in any step will STOP if a clarification or information is needed from the applicant, and resume after receiving the response.
- All days below are considered as working days.
- Total Performance Target calculated without the Business Validation.

<table>
<thead>
<tr>
<th>Phases of Renewal</th>
<th>No. of Waves</th>
<th>Total Performance target</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Business validation</strong></td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td><em>(section 5.1.2)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pricing</strong></td>
<td>1</td>
<td>30</td>
</tr>
<tr>
<td><em>(section 5.2)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Product licensing</strong></td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td><em>(section 5.3)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total performance target</strong>:</td>
<td></td>
<td><strong>40</strong></td>
</tr>
</tbody>
</table>
6. APPENDIX

6.1. Application Forms

<table>
<thead>
<tr>
<th>Application form</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marketing Authorization Application of Pharmaceutical Product</td>
<td>30</td>
</tr>
<tr>
<td>Application for Variation to a Marketing Authorization</td>
<td>61</td>
</tr>
</tbody>
</table>

Note:

- The application forms are available electronically in SDR system. These forms are only for viewing and preparing the required information before starting the process of submission.
طلب رخصة تسويق مستحضر دوائي

Marketing Authorization Application for Pharmaceutical Product
1 Type of Application

The following sections should be completed where appropriate.

This application concerns:
- Human medicinal product
- Herbal product
- Veterinary product

1.1 Please choose the type of product:

Human medicinal product
- New Drug (1.2.1.1)
- Biological Drug (1.2.1.2)
- Radiopharmaceutical Drug (1.2.1.3)
- Generic (Multisource) Drug (1.2.1.4)
- Health product (1.2.1.5)

Veterinary product
- New Drug (1.2.3.1)
- Biological Drug (1.2.3.2)
- Generic (Multisource) Drug (1.2.3.3)
- Health product (1.2.3.4)
- Herbal product (1.2.3.5)

1.2 Please provide the following information for the product:

1.2.1 Human medicinal product

1.2.1.1 New Drug Application
- New Chemical Entity (NCE)
Known active substance

1.2.1.1.1 Is Saudi Arabia the country of origin (COO)?

- Yes (go to section 2)
- No (complete the following information)

Product information in COO:
- Trade name:
- Product strength/unit:
- Dosage form:
- Marketing Authorization holder:
  - Name:
  - Address:
    - Line 1:
    - Line 2:
    - Line 3:
    - Postal/Zip code:
    - City:
    - Country:
  - Certifying Authority:
  - Date of authorization (dd/mm/yyyy):
  - Country:

1.2.1.1.2 Is the product registered in GCC?

- Yes, please specify the following
  - Registration number:
  - Trade name:
  - Committee meeting number:

- No
1.2.1.3 Is this product registered in SRA?

- Yes, please specify the SRA:
- No

1.2.1.4 Is this product under-license?

- Yes, please specify the MAH:
- No

1.2.1.5 Is this product from the SFDA exemption list?

- Yes, please choose the product:
- No

1.2.1.6 This product is candidate for:

- Abridge registration process
- Verification registration process
- Priority review process, please specify the SFDA letter number:
- None of the above

1.2.1.2 Biological Drug Application

- Biological
- Biosimilar
- Blood product
- Vaccine
- Others, please specify:

1.2.1.2.1 Is Saudi Arabia the country of origin (COO)?

- Yes (go to section 2)
- No (complete the following information)

Product information in COO:
- Trade name:
- Product strength/unit:
- Dosage form:
- Marketing authorization holder:
  - Name:
  - Address:
    - Line 1:
    - Line 2:
    - Line 3:
    - Postal/Zip code:
    - City:
    - Country:
- Certifying Authority:
- Date of authorization (dd/mm/yyyy):
- Country:

1.2.1.2.2 Is the product registered in GCC?
- Yes, please specify the following
  - Registration number:
  - Trade name:
  - Committee meeting number:
- No

1.2.1.2.3 Is this product registered in SRA?
- Yes, please specify the SRA:
- No

1.2.1.2.4 Is this product under-license?
- Yes, please specify the MAH:
1.2.1.2.5 Is this product from the SFDA exemption list?

- Yes, please choose the product:
- No

1.2.1.2.6 This product is candidate for:

- Abridge registration process
- Verification registration process
- Priority review process, please specify the SFDA letter number:
- None of the above

1.2.1.3 Radiopharmaceutical Drug Application

1.2.1.3.1 Is Saudi Arabia the country of origin (COO)?

- Yes (go to section 2)
- No (complete the following information)

Product information in COO:
- Trade name:
- Product strength/unit:
- Dosage form:
- Marketing authorization holder information in COO:
  - Name:
  - Address:
    - Line 1:
    - Line 2:
    - Line 3:
    - Postal/Zip code:
    - City:
    - Country:
1.2.1.3.2 Is the product registered in GCC?
   - Yes, please specify the following
     - Registration number:
     - Trade name:
     - Committee meeting number:
   - No

1.2.1.3.3 Is this product registered in SRA?
   - Yes, please specify the SRA:
   - No

1.2.1.3.4 Is this product under-license?
   - Yes, please specify the MAH:
   - No

1.2.1.3.5 Is this product from the SFDA exemption list?
   - Yes, please choose the product:
   - No

1.2.1.3.6 This product is candidate for:
   - Abridge registration process
   - Verification registration process
   - Priority review process, please specify the SFDA letter number:
   - None of the above

1.2.1.4 Generic (Multisource) Drug Application
1.2.1.4.1 Is Saudi Arabia the country of origin (COO)?
Yes (complete part 1.2.1.4.2)

No (complete the following information):

Product information:

- Trade name:
- Product strength/unit:
- Dosage form:
- Marketing Authorization holder:
  - Name:
  - Address:
    - Line 1:
    - Line 2:
    - Line 3:
    - Postal/Zip code:
    - City:
    - Country:
  - Date of authorization (dd/mm/yyyy):
  - Certifying Authority:
  - Country:

1.2.1.4.2 Reference Product Information:

- Trade name:
- Product strength/unit:
- Dosage form:

1.2.1.4.3 Is the product registered in GCC?

Yes, please specify the following

- Registration number:
- Trade name:
Committee meeting number:

- No

1.2.1.4.4 Is the product a 1st or 2nd Generic?

- Yes, please choose:
  - 1st Generic
  - 2nd Generic
- No

1.2.1.4.5 Is this product a 2nd Brand?

- Yes, please choose the Innovator product from the list:
- No

1.2.1.4.6 Is this product under-license?

- Yes, please specify the MAH:
- No

1.2.1.4.7 Is this product from the SFDA exemption list?

- Yes, please choose the product:
- No

1.2.1.4.8 Is this product candidate for Priority Review process?

- Yes, please specify the SFDA letter number:
- No

1.2.1.5 Health product Application

1.2.1.5.1 Is Saudi Arabia the country of origin (COO)?

- Yes (complete section 2)
- No (complete the following information)

Product information:

- Trade name:
• Product strength/unit:
• Dosage form:
• Marketing Authorization holder:
  o Name:
  o Address:
    ▪ Line 1:
    ▪ Line 2:
    ▪ Line 3:
    ▪ Postal/Zip code:
    ▪ City:
    ▪ Country:
  o Date of authorization (dd/mm/yyyy):
  o Certifying Authority:
  o Country:

1.2.1.5.2 Is this product under-license?
  ❑ Yes, please specify the MAH:
  ❑ No

1.2.2 Herbal product

Is Saudi Arabia the country of origin (COO)?
  ❑ Yes (go to section 2)
  ❑ No (complete the following information)

Product information in COO:
  ▪ Trade name:
  ▪ Product strength/unit:
Dosage form:

Marketing authorization holder information in COO:
  - Name:
  - Address:
    - Line 1:
    - Line 2:
    - Line 3:
    - Postal/Zip code:
    - City:
    - Country:
  - Date of authorization (dd/mm/yyyy):
  - Certifying Authority:
  - Country:

1.2.2.1.1 Is this product under-license?
  - Yes, please specify the MAH:
  - No

1.2.3 Veterinary product

1.2.3.1 New Drug Application
  - New Chemical Entity (NCE)
  - Known active substance

1.2.3.1.1 Is Saudi Arabia the country of origin (COO)?
  - Yes (go to section 2)
  - No (complete the following information)

Product information in COO:
  - Trade name:
- Product strength/unit:
- Dosage form:
- Marketing Authorization holder:
  - Name:
  - Address:
    - Line 1:
    - Line 2:
    - Line 3:
    - Postal/Zip code:
    - City:
    - Country:
  - Certifying Authority:
  - Date of authorization (dd/mm/yyyy):
  - Country:

**1.2.3.1.2 Is the product registered in GCC?**

- Yes, please specify the following
  - Registration number:
  - Trade name:
  - Committee meeting number:

- No

**1.2.3.1.3 Is this product registered in SRA?**

- Yes, please specify the SRA:

- No

**1.2.3.1.4 Is this product under-license?**

- Yes, please specify the MAH:

- No
1.2.3.1.5 Is this product from the SFDA exemption list?
- Yes, please choose the product:
- No

1.2.3.1.6 This product is candidate for:
- Abridge registration process
- Verification registration process
- Priority review process, please specify the SFDA letter number:
- None of the above

1.2.3.2 Biological Drug Application
- Biological
- Biosimilar
- Blood product
- Vaccine
- Others (please specify):

Is Saudi Arabia the country of origin (COO)?
- Yes (go to section 2)
- No (complete the following information)

Product information in COO:
- Trade name:
- Product strength/unit:
- Dosage form:
- Marketing authorization holder:
  - Name:
  - Address:
    - Line 1:
- Line 2:
- Line 3:
- Postal/Zip code:
- City:
- Country:
  - Certifying Authority:
  - Date of authorization (dd/mm/yyyy):
  - Country:

1.2.3.2.1 Is the product registered in GCC?
- Yes, please specify the following
  - Registration number:
  - Trade name:
  - Committee meeting number:
- No

1.2.3.2.2 Is this product registered in SRA?
- Yes, please specify the SRA:
- No

1.2.3.2.3 Is this product under-license?
- Yes, please specify the MAH:
- No

1.2.3.2.4 Is this product from the SFDA exemption list?
- Yes, please choose the product:
- No

1.2.3.2.5 This product is candidate for:
- Abridge registration process
- Verification registration process
○ Priority review process, please specify the SFDA letter number:
○ None of the above

1.2.3.3 Generic (Multisource) Drug Application

1.2.3.3.1 Is Saudi Arabia the country of origin (COO)?
○ Yes (complete part 1.3.3.3.2)
○ No (complete the following information)

Product information:
- Trade name:
- Product strength/unit:
- Dosage form:
- Marketing Authorization holder:
- Name:
- Address:
  - Line 1:
  - Line 2:
  - Line 3:
  - Postal/Zip code:
  - City:
  - Country:
- Date of authorization (dd/mm/yyyy):
- Certifying Authority:
- Country:

1.2.3.3.2 Reference Product Information:
- Trade name:
- Product strength/unit:
Dosage form:

1.2.3.3.3 Is the product registered in GCC?

- Yes, please specify the following
  - Registration number:
  - Trade name:
  - Committee meeting number:
- No

1.2.3.3.4 Is the product a 1st or 2nd Generic?

- Yes, please choose:
  - 1st Generic
  - 2nd Generic
- No

1.2.3.3.5 Is this product a 2nd Brand?

- Yes, please choose the Innovator product from the list:
- No

1.2.3.3.6 Is this product under-license?

- Yes, please specify the MAH:
- No

1.2.3.3.7 Is this product from the SFDA exemption list?

- Yes, please choose the product:
- No

1.2.3.3.8 Is this product candidate for Priority Review process?

- Yes, please specify the SFDA letter number:
- No
1.2.3.4 Health product Application

Is Saudi Arabia the country of origin (COO)?

- Yes (complete section 2)
- No (complete the following information)

Product information:
- Trade name:
- Product strength/unit:
- Dosage form:
- Marketing Authorization holder:
  - Name:
  - Address:
    - Line 1:
    - Line 2:
    - Line 3:
    - Postal/Zip code:
    - City:
    - Country:
  - Date of authorization (dd/mm/yyyy):
  - Certifying Authority:
  - Country:

1.2.3.4.1 Is this product under-license?

- Yes, please specify the MAH:
- No

1.2.3.5 Herbal product Application
Is Saudi Arabia the country of origin (COO)?

- Yes (complete section 2)
- No (complete the following information)

**Product information:**
- Trade name:
- Product strength/unit:
- Dosage form:
- Marketing Authorization holder:
  - Name:
  - Address:
    - Line 1:
    - Line 2:
    - Line 3:
    - Postal/Zip code:
    - City:
    - Country:
  - Date of authorization (dd/mm/yyyy):
  - Certifying Authority:
  - Country:

**1.2.3.5.1 Is this product under-license?**

- Yes, please specify the MAH:
- No
2 Product Information Details

The following sections should be completed where appropriate.

2.1 Product information:

2.1.1 Proposed trade name in English:

2.1.2 Proposed trade name in Arabic:

2.1.3 Product number 1:

2.1.3.1 List the active substance(s):

☐ Single active substance

☐ Multiple active substances

<table>
<thead>
<tr>
<th>Name of active substance(s)</th>
<th>Operator</th>
<th>Quantity</th>
<th>Unit</th>
<th>Reference/Monograph standard</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2.1.3.2 List the excipient(s):

<table>
<thead>
<tr>
<th>Name of excipient(s)</th>
<th>Operator</th>
<th>Quantity</th>
<th>Unit</th>
<th>Reference/Monograph standard</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2.1.3.3 Pharmaco-therapeutic group: (Please use current ATC code)

<table>
<thead>
<tr>
<th>ATC Code</th>
<th>Group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Quantity operator: equal to, less than, more than, less than or equal to, more than or equal to, equivalent to, approximately equal to, range
No ATC code has been assigned

2.1.3.4 Raw plant materials: (for Herbal products only)

2.1.3.5 Scientific name, family: (for Herbal products only)

2.1.3.6 Traditional or common name (Arabic and/or English): (for Herbal products only)

2.1.3.7 Used parts: (for Herbal products only)

2.1.3.8 Dosage form:

2.1.3.9 Strength

2.1.3.10 Unit of strength:

2.1.3.11 Package size: 1 value only

<table>
<thead>
<tr>
<th>Package size</th>
<th>Volume</th>
<th>Unit of Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2.1.3.12 Route of administration:

2.1.3.13 Administration device (if applicable):

2.1.3.14 Primary packaging:

2.1.3.15 Secondary packaging:

2.1.3.16 Is a GTIN assigned for this pack?

- Yes, please specify the value:
- No

2.1.3.17 Proposed shelf life:

2.1.3.18 Proposed shelf life after first opening (if applicable):

2.1.3.19 Proposed shelf life after reconstitution or dilution (if applicable):

2.1.3.20 Proposed storage conditions:

2.1.3.21 Proposed storage conditions after first opening (if applicable):

2.1.3.22 Reference Pharmacopoeia:
2.1.3.23 Do you have a Certificate of a Pharmaceutical Product (CPP)?

☐ Yes
☐ No

If not, do you have a marketing authorization (or free sales) certificate from the country of origin (COO)?

☐ Yes
☐ No

2.1.3.24 List and specify any material of animal source contained in any component of the product, if applicable:

<table>
<thead>
<tr>
<th>Material</th>
<th>Animal</th>
<th>Animal part</th>
<th>Free from BSE/TSE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>□</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□</td>
</tr>
</tbody>
</table>

- Please note that any pork content has to be clearly specified.
- It should be noted that all material used must be free from BSE/TSE. If a certificate confirming that the product is free from BSE/TSE is available, it should be provided.

2.1.3.25 Maximum Residual Limit (MRL) Status: (only for food producing species)

<table>
<thead>
<tr>
<th>Substance(s)</th>
<th>Species</th>
<th>Target tissue(s)</th>
<th>MRL</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2.1.3.26 Withdrawal Period:

2.1.3.27 Withdrawal Period Unit:
3 Manufacturers Details:

The following sections should be completed where appropriate.

### 3.1 Active Pharmaceutical Ingredient (API) manufacturers:

<table>
<thead>
<tr>
<th>Name of manufacturer</th>
<th>Name of ingredient</th>
<th>Address⁹</th>
<th>Phone</th>
<th>Fax</th>
<th>Activity¹⁰</th>
<th>Is it GMP certified?</th>
<th>Certifying Authority</th>
<th>Date of certification (dd/mm/yyyy)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 3.2 Excipients manufacturers:

<table>
<thead>
<tr>
<th>Name of manufacturer</th>
<th>Name of excipient</th>
<th>Address¹⁰</th>
<th>Phone</th>
<th>Fax</th>
<th>Activity¹⁰</th>
<th>Is it GMP certified?</th>
<th>Certifying Authority</th>
<th>Date of certification (dd/mm/yyyy)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 3.3 Finished Product manufacturers:

<table>
<thead>
<tr>
<th>Name of manufacturer</th>
<th>Address¹⁰</th>
<th>Phone</th>
<th>Fax</th>
<th>Activity¹⁰</th>
<th>Is it GMP certified?</th>
<th>Certifying Authority</th>
<th>Date of certification (dd/mm/yyyy)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

⁹ Full address as Line 1, 2 & 3; Postal/Zip code, City & Country
4 Marketing Authorization Details

The following sections should be completed where appropriate.

4.1 Marketing authorization holder legally responsible for placing the product on the market in KSA\(^\text{11}\):

- Company Name:
- Address:
  - Line 1:
  - Line 2:
  - Line 3:
  - Postal/Zip code:
  - City:
  - Country:
- Phone:
- Fax:
- E-Mail:

4.2 Person authorized for communication in KSA on behalf of the applicant:

- Person Name:
  - First name:
  - Middle name:
  - Family/last name:
- Company Name\(^\text{12}\):

\(^{11}\) A drop-down menu (transferred from DENR or Re-engineered system after normalization)

\(^{12}\) A drop-down menu (transferred from DENR or Re-engineered system after normalization)
• Address:
  o Line 1:
  o Line 2:
  o Line 3:
  o Postal/Zip code:
  o City:
  o Country:
• Phone:
• Fax:
• E-Mail:

4.3 Person/Company authorized for communication between the marketing authorization holder and the SFDA after authorization, if different from 3.2 in KSA:

• Person Name:
  o First name:
  o Middle name:
  o Family/last name:
• Company Name13:
• Address:
  o Line 1:
  o Line 2:
  o Line 3:
  o Postal/Zip code:

13 A drop-down menu (transferred from DENR or Re-engineered system after normalization)
4.4 Person qualified for Pharmacovigilance in KSA:

- Name:
  - First name:
  - Middle name:
  - Family/last name:

- Address:
  - Line 1:
  - Line 2:
  - Line 3:
  - Postal/Zip code:
  - City:
  - Country:

- Phone:
- Fax:
- E-Mail:
5 Scientific Advice

5.1 Was there any formal scientific advice given by the SFDA for this medicinal product?

- Yes, please complete the following:
  - Date (dd/mm/yyyy):
  - Reference number of the scientific advice letter:

- No

6 Pediatric Development Program

6.1 Is there a pediatric development program for this medicinal product?

- Yes, please indicate the relevant section(s) in the dossier:

- No
7 Legal Status of the Product

The following sections should be completed where appropriate.

7.1 Proposed dispensing classification:

- Subject to medical prescription:
  - By a licensed doctor in the KSA:
    - Consultant
    - Senior Assistant
    - Assistant
    - GP
  - Restricted prescription
  - Special distribution program
  - Hospital-only item

- Not subject to medical prescription:
  - By a licensed Pharmacist – Behind the counter (BTC)
  - Over the counter (OTC)
### Status of the application in other regulatory agencies

Tick the appropriate box and fill the information.

#### Authorized

List all countries where the product is authorized for marketing:

<table>
<thead>
<tr>
<th>Country</th>
<th>Trade name</th>
<th>Product strength/unit</th>
<th>Dosage form</th>
<th>Marketing authorization holder</th>
<th>Date of authorization (dd/mm/yyyy)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Pending

List all countries where the product application is pending:

<table>
<thead>
<tr>
<th>Country</th>
<th>Trade name</th>
<th>Product strength/unit</th>
<th>Dosage form</th>
<th>Date of submission (dd/mm/yyyy)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Refused

List all countries where the product has been refused for marketing:

<table>
<thead>
<tr>
<th>Country</th>
<th>Trade name</th>
<th>Product strength/unit</th>
<th>Dosage form</th>
<th>Reason for refusal</th>
<th>Date of refusal (dd/mm/yyyy)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Withdrawn (by applicant after authorization)

List all countries where the product has been withdrawn after authorization:

<table>
<thead>
<tr>
<th>Country</th>
<th>Trade name</th>
<th>Product strength/unit</th>
<th>Dosage form</th>
<th>Date of withdrawal (dd/mm/yyyy)</th>
<th>Reason for withdrawal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Suspended/revoked (by competent authority)

List all countries where the product has been suspended or revoked:

<table>
<thead>
<tr>
<th>Country</th>
<th>Trade name</th>
<th>Product strength/unit</th>
<th>Dosage form</th>
<th>Date of suspension/revocation (dd/mm/yyyy)</th>
<th>Reason for suspension/revocation:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
9 Price Certificate Form

The following sections should be completed where appropriate.

9.1 Ex-Factory Price:
9.1.1 Country of Origin’s currency

9.2 Wholesale Price
9.2.1 Country of Origin’s currency

9.3 Public price
9.3.1 Country of Origin’s currency

9.4 Proposed CIF to KSA
9.4.1 Currency

9.5 The other price in countries where the product is marketed:

<table>
<thead>
<tr>
<th>No</th>
<th>Country Name</th>
<th>Pack Size</th>
<th>Ex-Factory Price</th>
<th>Currency</th>
<th>CIF Price</th>
<th>Currency</th>
<th>Public Price</th>
<th>Currency</th>
<th>notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Algeria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Australia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Argentina</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Bahrain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Belgium</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Canada</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Cyprus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Denmark</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Egypt</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>France</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Country Name</td>
<td>Pack Size</td>
<td>Ex-Factory Price</td>
<td>Currency</td>
<td>CIF Price</td>
<td>Currency</td>
<td>Public price</td>
<td>Currency</td>
<td>notes</td>
</tr>
<tr>
<td>----</td>
<td>--------------</td>
<td>-----------</td>
<td>------------------</td>
<td>----------</td>
<td>-----------</td>
<td>----------</td>
<td>--------------</td>
<td>----------</td>
<td>-------</td>
</tr>
<tr>
<td>11</td>
<td>Germany</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Greece</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Holland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Hungary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Ireland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Italy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Jordan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Kuwait</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>New Zealand</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Oman</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Portugal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Lebanon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Japan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>South Korea</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Spain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Sweden</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Switzerland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Turkey</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>UAE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>UK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>Others</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Declaration:

I hereby certify that the submitted information is true and accurate and changes will not be made until they are approved by SFDA.

Title:

Name:

Signature:

Date:

Company stamp:
طلب تعديل رخصة التسويق

Application for Variation to a Marketing Authorization
1 Request type

1.1 This application concerns:

- Administrative Changes
- Quality Changes
- Safety, Efficacy, or Pharmacovigilance Changes
2 Type(s) of variation(s):

2.1 Variations included in this application:

<table>
<thead>
<tr>
<th>Number and title of variation, as per the guideline(^{14})</th>
<th>Procedure Type</th>
<th>Date of Implementation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2.2 Precise scope and background for change (Include a description and background of all the proposed changes with its proposed Classification)

<table>
<thead>
<tr>
<th>Current</th>
<th>Proposed</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2.3 Does this change affect the last updated drug application form?

☐ Yes, which part? Please specify to the lowest level and state the new value:

☐ Section 2 - Product Information Details: Please choose the field(s) and type the new value

☐ Section 3 - Manufacturers Details: Please choose the field(s) and type the new value

\(^{14}\) Choose from the drop-down menu of all variations in the GCC variation guideline
☐ Section 4 - Marketing Authorization Details: Please choose the field(s) and type the new value

☐ Section 7 - Legal Status of the Product: Please choose the field(s) and type the new value

☐ Section 9 - Price Certificate Form: Please choose the field(s) and type the new value

No

Declaration:

I hereby certify that the submitted information is true and accurate and changes will not be made until they are approved by SFDA.

Title:

Name:

Signature:

Date:

Company stamp: